Redeye is favorable to the further validation of Nevisense in the US.
Redeye returns with an updated view of Saniona following the Q2 report and recent progress.
Det svaga utfallet under andra kvartalet föranleder ytterligare nedjusteringar på våra prognoser.
Med stark krona och fortsatt restriktiv penningpolitik är utsikterna för resten av året inte särskil...
Redeye updates on Maximum Entertainment post Q2-results where topline was somewhat soft while EBITDA...
Redeye updates its view on Verve Group following its Q2 2024 report, which was in line with the stro...
Solwers posted H1 revenue 3% ahead of our estimate, as organic growth was slightly positive, while w...
Redeye saw sales development that was far better than our expectations.
Redeye states that Systemair's Q1 report only offered a couple of minor surprises.
Tangiamo Touch Technology (”Tangiamo” eller ”Bolaget”) publicerade den 30 augusti 2024 bolagets delå...
Redeye comments on BioInvent's Q2 report 2024. Positive new results from BI-1206 in lymphoma and sol...
Idag, fredag 30 augusti, offentliggjorde Enrad AB (”Enrad” eller ”Bolaget”) sin rapport för kv2 2024...
SmartCrafts andra kvartal visar på en fortsatt stark tillväxt i både omsättning och ARR.
En väsentlig osäkerhetsfaktor om hur stort det avslutade högvolymprogrammet var har nu lyfts från ak...
AlzeCure fortsätter att generera nya positiva data för sina projekt, vilket ökar möjligheterna när d...
Redeye return with a research update following BioArctic's Q2 report and recent events, and largely ...
MODI reported Q2’24 sales largely in line with last year, at SEK 7.
Redeye saw sales that were markedly above and results that were in line with our expectations.
Solwers posted H1 revenue of EUR 39.9m, 2% above our expectations while profitability was lower due ...
Redeye returns with a more detailed take on the Q1 report.
